Feb 15 Masimo Corp :
* Masimo announces CE marking of respiration rate measurement on MightySat Rx Source text for Eikon: Further company coverage:
BRIEF-MTBC announces $7.4 mln public offering
* Medical Transcription Billing - intends to use net proceeds from offering, for repayment of debt, working capital and general corporate purposes
UPDATE 1-Novartis breast cancer drug Kisqali wins European panel backing
ZURICH, June 23 A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.